Patents by Inventor Corey Don Anderson

Corey Don Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230373974
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions, containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies, and processes and intermediates for making such modulators.
    Type: Application
    Filed: October 6, 2021
    Publication date: November 23, 2023
    Inventors: Jason MCCARTNEY, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Thomas CLEVELAND, Timothy A. DWIGHT, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Mark Thomas MILLER, Alina SILINA, Jinglan ZHOU
  • Publication number: 20230365587
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies, and processes and intermediates for making such modulators.
    Type: Application
    Filed: October 6, 2021
    Publication date: November 16, 2023
    Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy A. DWIGHT, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Paul KRENITSKY, Mark Thomas MILLER, Fabrice PIERRE, Alina SILINA, Jinglan ZHOU
  • Patent number: 11591350
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: February 28, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Patent number: 11584761
    Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: February 21, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Publication number: 20220372047
    Abstract: Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.
    Type: Application
    Filed: April 2, 2020
    Publication date: November 24, 2022
    Inventors: Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy A. DWIGHT, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Paul KRENITSKY, Jason MCCARTNEY, Vito MELILLO, Mark Thomas MILLER, Alina SILINA, Johnny UY, Jinglan ZHOU
  • Publication number: 20220313698
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: August 13, 2020
    Publication date: October 6, 2022
    Inventors: Alexander Russell Abela, Corey Don Anderson, Brett C. Bookser, Brett B. Busch, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Yoshihiro Ishihara, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Andreas Termin, Sara E. Swift, Johnny Uy, Carl V. Vogel, Jinglan Zhou
  • Publication number: 20220106331
    Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: May 18, 2021
    Publication date: April 7, 2022
    Inventors: Jeremy J. Clemens, Alexander Russell Abela, Corey Don Anderson, Brett B. Busch, Weichao George Chen, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Ping Kang, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Andreas Termin, Johnny Uy, Carl V. Vogel, Jinglan Zhou
  • Publication number: 20220047564
    Abstract: This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. (I) The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.
    Type: Application
    Filed: November 13, 2019
    Publication date: February 17, 2022
    Inventors: David M. ALTSHULER, Corey Don ANDERSON, Bartlomiej BOREK, Weichao George CHEN, Jeremy J. CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Bryan FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Brian J. HARE, Reshma KEWALRAMANI, Jason McCARTNEY, Mark Thomas MILLER, Prasuna PARASELLI, Fabrice PIERRE, Sarah M. ROBERTSON, Patrick R. SOSNAY, Sara E. SWIFT, Fredrick VAN GOOR, Tim YOUNG, Jinglan ZHOU
  • Patent number: 11066417
    Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: July 20, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy J. Clemens, Alexander Russell Abela, Corey Don Anderson, Brett B. Busch, Weichao George Chen, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Ping Kang, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Andreas Termin, Johnny Uy, Carl V. Vogel, Jinglan Zhou
  • Publication number: 20210047345
    Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 13, 2020
    Publication date: February 18, 2021
    Inventors: Paul Angell, John E. Cochran, Benjamin J. Littler, David Siesel, Armando Urbina, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Publication number: 20210047323
    Abstract: Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: August 13, 2020
    Publication date: February 18, 2021
    Inventors: Yi Shi, Kevin J. Gagnon, Jicong Li, Jennifer Lu, Ales Medek, Muna Shrestha, Michael Waldo, Beili Zhang, Carl L. Zwicker, Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Publication number: 20210047350
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: August 13, 2020
    Publication date: February 18, 2021
    Inventors: Corey Don Anderson, Jeremy J. Clemens, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Peter Grootenhuis, Sara Sabina Hadida Ruah, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Jinglan Zhou
  • Publication number: 20190248809
    Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: February 14, 2019
    Publication date: August 15, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy J. Clemens, Alexander Russell Abela, Corey Don Anderson, Brett B. Busch, Weichao George Chen, Thomas Cleveland, Timothy Richard Coon, Bryan Frieman, Senait G. Ghirmai, Peter Grootenhuis, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Ping Kang, Haripada Khatuya, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Pierre, Sara E. Swift, Andreas Termin, Johnny Uy, Carl V. Vogel, Jinglan Zhou
  • Patent number: 7846954
    Abstract: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: December 7, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Nicole Zimmermann, Peter D. J. Grootenhuis, Mehdi Michel Djamel Numa, Dean Stamos, Corey Don Anderson, Tara Whitney
  • Patent number: 7842686
    Abstract: The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: November 30, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Corey Don Anderson, Andreas P. Termin, Pramod Joshi, Sara S. Hadida Ruah, Daniele Bergeron, Sanghee Yoo, Jingrong Cao
  • Publication number: 20100004300
    Abstract: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: July 1, 2009
    Publication date: January 7, 2010
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Nicole Zimmermann, Peter D.J. Grootenhuis, Mehdi Michel Djamel Numa, Dean Stamos, Corey Don Anderson, Tara Whitney
  • Publication number: 20090186882
    Abstract: The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.
    Type: Application
    Filed: January 21, 2009
    Publication date: July 23, 2009
    Inventors: Corey Don Anderson, Andreas P. Termin, Pramod Joshi, Sara S. Hadida Ruah, Daniele Bergeron, Sanghee Yoo